生物疗法对心血管风险关键参数的影响在牛皮队列-a回顾性审查中

相关实验视频

Updated: Jun 27, 2025

02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

378

Joseph Joseph^1,2, Kelvin Truong^1,2, Serigne N Lo^1,3

¹Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Dermatology and therapy

|April 25, 2024

概括

生物疗法显著改善了牛皮的皮肤严重程度,但在患有牛皮的患者中一年后没有改变心血管疾病风险因素,如血压或BMI.

科学领域:

皮肤病学和心血管医学
免疫皮肤学免疫皮肤学
临床研究临床研究

背景情况:

牛皮是心血管疾病 (CVD) 的已知危险因素.
生物药物代表了管理牛皮皮肤病变的突破.
这项研究调查了持续生物治疗对牛皮患者心血管疾病风险因素的影响.

研究的目的:

在慢性斑块牛皮患者连续生物治疗一年后,评估心血管风险因素的变化.
评估皮肤改善和心血管风险标志物之间的关系.

主要方法:

对106名慢性斑块性牛皮患者进行了回顾性审查,这些患者接受了生物治疗.
牛皮区域和严重程度指数 (PASI) 用于测量皮肤改善.
评估的心血管风险因素包括身体质量指数 (BMI),静缩血压 (SBP),静缩血压 (DBP) 和心率 (HR).
配对的t测试比较了基线和1年的随访测量.

主要成果:

牛皮的严重程度显著改善 (PASI从17.4降至1.4,p < 0.001).
在治疗1年后,没有观察到SBP,DBP,BMI或HR的统计学意义上的变化.
基线平均BMI为30kg/m2,没有观察到显著变化.

结论:

一年持续的生物治疗导致牛皮患者的皮肤明显改善.
尽管有显著的皮肤病益处,生物疗法在研究期间没有证明改善了关键心血管疾病风险因素.
需要进一步的研究来探索这种患者群体的长期心血管结果和潜在干预措施.

关键词:

生物疗法是一种生物疗法.心血管疾病是什么心血管疾病心血管疾病的危险因素牛皮是一种病.追溯审查是回顾性审查.

相关概念视频

01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...

01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

125

01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

422

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

422

01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

169

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

169

01:20

The JAK-STAT Signaling Pathway

8.8K

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...